CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice.
Antigen-specific IgE plays an important role in the pathogenesis of allergic disorders. Immunostimulatory CpG motifs (CpG) in bacterial DNA or synthesized oligodeoxynucleotides (ODN) are gaining recognition as potential immunomodulators for switching on protectiveT(h)1-mediated immunity and preventing or potentially inhibiting T(h)2-dependent allergic responses. To date, allergic models used in CpG ODN studies have been established by immunization of mice with allergen in the presence of adjuvant. This, in addition to failure to assess specific IgE production in most of the studies, has limited understanding of the role of CpG ODN vaccination in allergic responses. Here, we examine the effects of synthesized CpG ODN on both developing and ongoing IgE responses in mice sensitized using a recombinant mosquito salivary antigen (rAed a 2) without adjuvant. Pretreatment of mice with CpG ODN mixed with rAed a 2 successfully inhibited subsequent induction of serum rAed a 2-specific IgE (but not IgG1) and antigen-induced IL-4 and IL-5 production in spleen cells. This was associated with an increase of serum IgG2a and IL-12, and increased IFN-gamma and IL-12 production by spleen cells. In this model, however, co-administration of CpG ODN with rAed a 2 to presensitized mice failed to down-regulate ongoing IgE responses despite significant up-regulation of serum IL-12 and specific IgG2a. Strikingly, a transient skin delayed-type hypersensitivity reaction occurred in CpG ODN-treated mice. These observations provide a new insight into the potential therapeutic application of CpG ODN to allergic disorders.
Peng
Z
Z
Section of Allergy and Clinical Immunology, Department of Pediatrics and Child Health, and Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba R3E 3P5, Canada.
Wang
H
H
Mao
X
X
HayGlass
K T
KT
Simons
F E
FE
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000330:Aedes / Q000276:immunology; D000485:Allergens / Q000008:administration & dosage / Q000276:immunology; D000818:Animals; D018899:CpG Islands / Q000276:immunology*; D015536:Down-Regulation / Q000276:immunology*; D005260:Female; D007073:Immunoglobulin E / Q000096:biosynthesis*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007271:Injections, Intradermal; D019476:Insect Proteins / Q000008:administration & dosage / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage / Q000276:immunology*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology; D012471:Salivary Proteins and Peptides / Q000008:administration & dosage / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000485:Allergens; C408982:CPG-oligonucleotide; D007166:Immunosuppressive Agents; D019476:Insect Proteins; D009838:Oligodeoxyribonucleotides; D011994:Recombinant Proteins; D012471:Salivary Proteins and Peptides; D019444:Vaccines, DNA; D007073:Immunoglobulin E